Clinical Trial Technology

Outcome Prediction After Surgery and Chemoradiation of Squamous Cell Carcinoma in the Oral Cavity, Oropharynx, and Hypopharynx: Use of Baseline Perfusion CT Microcirculatory Parameters vs. Tumor Volume

Publications

Outcome Prediction After Surgery and Chemoradiation of Squamous Cell Carcinoma in the Oral Cavity, Oropharynx, and Hypopharynx: Use of Baseline Perfusion CT Microcirculatory Parameters vs. Tumor Volume

Maecenas tempor, ex at maximus efficitur, felis sem ultrices ligula, ut hendrerit purus eros ac urna. Vestibulum ut vestibulum tortor. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Cras eu lectus quam. Nunc ligula arcu, auctor sit amet tellus eleifend, facilisis laoreet odio. Donec placerat urna eleifend blandit porttitor.

Nunc magna turpis, tristique at dictum vel, sollicitudin blandit felis. Morbi aliquam elit et pellentesque vulputate. Donec elementum, ante quis ornare porttitor, tortor dolor vestibulum velit, et viverra enim massa vitae ex.

ISMI: A Classification Index for High Angular Resolution Diffusion Imaging

Publications

ISMI: A Classification Index for High Angular Resolution Diffusion Imaging

Maecenas tempor, ex at maximus efficitur, felis sem ultrices ligula, ut hendrerit purus eros ac urna. Vestibulum ut vestibulum tortor. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Cras eu lectus quam. Nunc ligula arcu, auctor sit amet tellus eleifend, facilisis laoreet odio. Donec placerat urna eleifend blandit porttitor.

Nunc magna turpis, tristique at dictum vel, sollicitudin blandit felis. Morbi aliquam elit et pellentesque vulputate. Donec elementum, ante quis ornare porttitor, tortor dolor vestibulum velit, et viverra enim massa vitae ex.

Distance-Based Tractography in High Angular Resolution Diffusion Imaging

Publications

Distance-Based Tractography in High Angular Resolution Diffusion Imaging

Maecenas tempor, ex at maximus efficitur, felis sem ultrices ligula, ut hendrerit purus eros ac urna. Vestibulum ut vestibulum tortor. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Cras eu lectus quam. Nunc ligula arcu, auctor sit amet tellus eleifend, facilisis laoreet odio. Donec placerat urna eleifend blandit porttitor.

Nunc magna turpis, tristique at dictum vel, sollicitudin blandit felis. Morbi aliquam elit et pellentesque vulputate. Donec elementum, ante quis ornare porttitor, tortor dolor vestibulum velit, et viverra enim massa vitae ex.

Chronic Recurrent Multifocal Osteomyelitis in Children: A New, MRI-Based Method of Quantifying Inflammation in the Bone

Publications

Chronic Recurrent Multifocal Osteomyelitis in Children: A New, MRI-Based Method of Quantifying Inflammation in the Bone

Maecenas tempor, ex at maximus efficitur, felis sem ultrices ligula, ut hendrerit purus eros ac urna. Vestibulum ut vestibulum tortor. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Cras eu lectus quam. Nunc ligula arcu, auctor sit amet tellus eleifend, facilisis laoreet odio. Donec placerat urna eleifend blandit porttitor.

Nunc magna turpis, tristique at dictum vel, sollicitudin blandit felis. Morbi aliquam elit et pellentesque vulputate. Donec elementum, ante quis ornare porttitor, tortor dolor vestibulum velit, et viverra enim massa vitae ex.

MIMEDX and IAG Partner to Support Knee Osteoarthritis Ph 3 Clinical Trial Program

MIMEDX and IAG Partner to Support Knee Osteoarthritis Ph 3 Clinical Trial Program

Image Analysis Group to Partner with MIMEDX in Support of MIMEDX’s Knee Osteoarthritis Clinical Trial Program

Image Analysis Group to Provide Imaging Strategy and Advanced Imaging Analytics in Support of MIMEDX’s Knee Osteoarthritis Clinical Trial Program

MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts and IAG, Image Analysis Group, a strategic bio-pharma imaging expert announce a partnership in the development of MIMEDX’s mdHACM.

The IAG team has significant experience in using medical imaging to support drug development.

‘We have significant evidence that mdHACM injected into the knees of people with OA provides lasting pain relief and improves function, and we believe it has potential as a DMOAD. MIMEDX has discovered how to preserve the remarkable healing properties of placental membranes when we produce mdHACM, and we have demonstrated that it contains many proteins that influence the biology of cartilage-forming cells and reduce inflammation. We believe these active proteins contribute to the striking, long-lasting benefits we have seen in patients receiving a single injection of mdHACM into their osteoarthritic knee. Following an extensive review and selection process, we are very excited to have world-class partners who are at the forefront of advancing meaningful medicines; working in collaboration accelerates our ability to gather quality data for our future Biologics License Application (BLA), and our potential to bring tremendous benefit for people living with OA.’ said Dr Robert B. Stein, M.D., Ph.D., MIMEDX President, Regenerative Medicine & Biologics Innovation.

About Image Analysis Group (IAG):

IAG, Image Analysis Group is a unique clinical development partner to life sciences companies. We broadly leverage our proprietary image analysis methodologies, power of our cloud platform DYNAMIKA, years of experience in AI and Machine Learning as well as bespoke co-development business models to ensure higher probability for promising therapeutics to reach the patients. Our independent Bio-Partnering division fuses risk-sharing business models and agile culture to accelerate novel drug development.

About MIMEDX: 

MIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental tissue engineering, we have both a commercial business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments.

For more information, please reach out to: imaging.experts@ia-grp.com

READ NEXT CASE STUDY >

Supporting Advance Imaging Research in Psoriatic Arthritis Treatment

Supporting Advance Imaging Research in Psoriatic Arthritis Treatment

Academic and Clinical Opinion Leaders and Image Analysis Group Collaborate to Advance Research in Psoriatic Arthritis Treatment.

London, UK — Image Analysis Group, a pioneer in medical imaging research and analysis, have joined forces in a strategic collaboration with renowned academic and clinical opinion leaders aimed at advancing research in the treatment of Psoriatic Arthritis, study MOSAIC, ClinicalTrials.gov Identifier: NCT03783026.

Amgen, known for its commitment to innovative therapies, recently presented the results of MOSAIC and its clinically relevant research findings on Otezla (Apremilast) in Psoriatic Arthritis during the European League Against Rheumatism (EULAR) 2023 annual meeting. The study, titled “Apremilast Reduces Inflammation as Measured by MRI of the Hand in Patients With Psoriatic Arthritis: Primary Results from the Phase 4 MOSAIC Study,” showcased the potential of Apremilast in reducing inflammation, as assessed through MRI scans of the hand.

This work is done in collaboration with MOSAIC study Primary Investigators Prof. Mease and Prof. Ostergaard, number of academic institutions and Image Analysis Group, an organization specializing in advanced medical imaging analysis and research.

This phase 4 trial and collected imaging and clinical data mark a significant step forward in drug developers’ mission to improve the lives of individuals affected by Psoriatic Arthritis. By harnessing the expertise and cutting-edge methodologies and advanced technology platform DYNAMIKA, Image Analysis Group and the collaborators aim to explore and quantify the impact of Apremilast on patients’ lives.

Image Analysis Group’s dedication to developing precise and comprehensive imaging solutions aligns seamlessly with Amgen’s commitment to scientific innovation, said Dr. Olga Kubassova, CEO of IAG.

We are excited to work in this trial with this dedicated group of people, so that our expertise in medical imaging analysis can support understanding and treatment of Psoriatic Arthritis, said Prof. Mikael Boesen, Sn Therapeutic Lead for Musculoskeletal Research at IAG and Head of musculoskeletal imaging and research, Bispebjerg and Frederiksberg Hospital, Radiology, Department of Overlæge, Professor, Bispebjerg and Frederiksberg Hospital, The Parker Institute , Denmark.

This work with Amgen and all collaborators signifies a shared vision of improving patient outcomes through innovation and imaging research.

For media inquiries, interview requests, or further information about this collaboration, please contact

imaging.experts@ia-grp.com

Image Analysis Group (IAG)

IAG, a pioneering imaging Clinical Research Organization (iCRO), seamlessly blends medical acumen, operational excellence, and cutting-edge AI to accelerate drug development. Since 2007, we’ve been the trusted partner for global biotech and pharma, expertly managing imaging across Phase I-III trials and real-world evidence studies in diverse therapeutic areas.

Our award-winning DYNAMIKA platform ensures unparalleled data integrity, while our innovative approach consistently unlocks and amplifies the value of novel therapies.

Partner with IAG to transform your clinical trials and maximize your therapeutic asset’s market potential.

READ NEXT CASE STUDY >

OBESITY and SARCOPENIA

BODY COMPOSITION

When conducting an obesity trial to measure body composition, it’s important to choose imaging options that provide accurate and reliable results. Here are some of the best imaging modalities commonly used for this purpose:

  • Dual-Energy X-ray Absorptiometry (DXA): DXA scans are highly accurate and are considered the gold standard for measuring body composition. They can provide information about bone density, fat mass, and lean mass.
  • Computed Tomography (CT) Scan: CT scans can offer detailed information about fat distribution within the body, allowing for precise measurements of visceral and subcutaneous fat.
  • Magnetic Resonance Imaging (MRI): MRI can provide excellent visualization of fat and lean tissue, offering insights into body composition. It’s non-invasive and does not involve radiation.
  • Bioelectrical Impedance Analysis (BIA): While not an imaging modality in the traditional sense, BIA uses electrical impedance to estimate body composition. It’s relatively simple and cost-effective.
  • Ultrasound: Ultrasound imaging can be used to assess the subcutaneous fat thickness and muscle thickness at specific locations, making it useful for localized body composition measurements.
  • Air Displacement Plethysmography (ADP): ADP, commonly measured using the BodPod, calculates body composition based on the principles of air displacement. It’s non-invasive and provides accurate results.
  • Positron Emission Tomography (PET) Scan: PET scans can be used to assess metabolic activity in fat tissue, providing insights into obesity-related metabolic changes.

The choice of imaging modality should depend on factors such as the specific research goals, budget, and accessibility of equipment. It’s often advisable to consult with a medical imaging expert or radiologist to determine the most suitable option for your obesity trial. Additionally, consider ethical and safety aspects when conducting imaging studies involving human participants

About IAG, Image Analysis Group

IAG is a unique partner to life sciences companies developing new treatment and driving the hope of the up-coming precision medicine. IAG leverages expertise in medical imaging and the power of DYNAMIKA™, our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes.

Acting as imaging Contract Research Organization, IAG’s experts also recognize the significance of a comprehensive approach to asset development. They actively engage in co-development projects with both private and public sectors, demonstrating a commitment to cultivating collaboration and advancing healthcare solutions.

Contact our expert team: imaging.experts@ia-grp.com

READ NEXT CASE STUDY >
Experience: Scoring Systems
  • Eligibility and Safety Assessments
  • Body Mass Index (BMI) Score
  • Visceral Adiposity Index (VAI)
  • Fat Mass Index (FMI)
  • Fat-Free Mass Index (FFMI)
  • Total Body Fat Percentage
  • Sarcopenia Index
  • Epicardial Fat Volume Score
  • Liver Fat Score
  • Muscle Quality Score
  • Phase Angle (PhA)
Experience: Imaging
  • MRI
  • DEXA
  • CT
  • PET, PET-CT
  • Ultrasound
  • ADP
  • BIA
Publications

Since 2007, over 2000 articles were published to cover scientific discoveries, technology break-throughs and special cases. We list here some critically important papers and abstracts.

Testimonials

Combining our technologies and business advisory services with promising life science companies has yielded spectacular results over the past five years. As a trusted partner to many biotech and pharma companies, IAG’s team is proud to share your words and quotes.

Supportting Advance Imaging Research in Women’s Reproductive Health

Supportting Advance Imaging Research in Women’s Reproductive Health

Ferring Pharmaceuticals and Image Analysis Group Collaborate to Advance Research in the complex field of pregnancy.

London, UK — Image Analysis Group, a leader in medical imaging, have joined forces in a strategic collaboration with Ferring Pharmaceuticals to advance Women’s Reproductive Health through AI-driven medical image analysis.

Dr. Philippe Pinton, Senior Vice President, Head of Clinical and Translational Sciences, Global R&D at Ferring Pharmaceuticals, stated, “Our collaboration with IAG is a testament to our commitment to AI-driven research in the complex field of pregnancy.”

Dr. Olga Kubassova, CEO of IAG, added, “We are excited to support the Ferring team in leveraging AI to gain deeper insights into women’s reproductive health, ultimately aiming to enhance the chances of a healthy pregnancy for women globally.”

IAG’s mission is to assist pharmaceutical partners in efficiently developing transformative medicines. This is achieved through their expertise in medical imaging and AI, utilizing their proprietary platform, DYNAMIKA. This platform is designed to efficiently manage large volumes of imaging data in multi-centre trials and incorporates integrated AI modules. The partnership promises innovative approaches to improve women’s health worldwide.

For media inquiries, interview requests, or further information about this collaboration, please contact

imaging.experts@ia-grp.com

About Image Analysis Group: Image Analysis Group is a leading advanced medical imaging research and analysis services provider. With a focus on precision and scientific rigour, Image Analysis Group collaborates with pharmaceutical companies, research institutions, and healthcare providers to enhance the understanding of diseases and support the development of novel treatments.

READ NEXT CASE STUDY >